IDH1 and central nervous system cancer: An implication of these findings—the heterogeneity among the studied IDH wild-type cases—is that the clinical, therapeutic data of glioma cases should be studied in correlation to their in situ metabolic protein expression profiles, especially in case of mTORI and temozolomide treatment resistant patients (e.g. tumour pairs before and after treatments).